Academic Journal
Q2Cancer Chemotherapy and Pharmacology
About Cancer Chemotherapy and Pharmacology
About Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology is a peer-reviewed scholarly journal published by Springer Science and Business Media Deutschland GmbH (Germany). It focuses on Q2. Publication coverage spans 1978-2026.
Key indicators: ISSN 1432-0843, 0344-5704; H-index 132.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (132): Exceptionally high — 132 articles have each been cited at least 132 times. This indicates deep, sustained influence in the field.
Publishing in Cancer Chemotherapy and Pharmacology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Cancer Chemotherapy and Pharmacology?
1432-0843, 0344-5704.
Who publishes Cancer Chemotherapy and Pharmacology?
Springer Science and Business Media Deutschland GmbH.
What are Cancer Chemotherapy and Pharmacology's metrics?
H-index 132.
Where do I submit to Cancer Chemotherapy and Pharmacology?
Via the official website.
Is Cancer Chemotherapy and Pharmacology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Cancer Treatment and Pharmacology; Cancer therapeutics and mechanisms; Colorectal Cancer Treatments and Studies; Lung Cancer Research Studies; Lung Cancer Treatments and Mutations; Chemotherapy-induced organ toxicity mitigation.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,390.00 USD; 3,690.00 EUR; 2,890.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Longitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study
Yoshiharu Motoo, Katsunori Shinozaki, Masatomo Miura, Tsuyoshi Takagi et al.
2026-10-14 · DOI: 10.1007/s00280-026-04959-wResearch and development of a multi-target HER2 inhibitor (CPD 1) and its mechanism and application in combating HER2-positive breast cancer
Jianchao Pan, Wenqing Zhang, Xiang Yang
2026-10-12 · DOI: 10.1007/s00280-026-04967-wAntibody–drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges
Yilin Zhao, Xiaoran Ma, Xiaozhen Liu, Li Yan et al.
2026-10-12 · DOI: 10.1007/s00280-026-04964-zBeyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy
Ghassan Sonji, Nada Sonji, Afaf El Katerji
2026-10-09 · DOI: 10.1007/s00280-026-04963-0Risk factors for immune-related adverse events associated with pembrolizumab in patients with solid tumors
Farah Shkakhwa, Farah Basbous, Dalia Shakhatreh, Kamal Al-Rabi et al.
2026-10-09 · DOI: 10.1007/s00280-026-04968-9Pharmacological targeting of xCT/system Xc− to modulate temozolomide sensitivity in glioma and glioblastoma preclinical models: a focused systematic review
Sufyan Elhashani, Mohamed Elkawafi, Abdalmanam El Shekhi, Sanad Elrishe et al.
2026-10-09 · DOI: 10.1007/s00280-026-04957-yPROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification
Sanket Nagmoti, Eshita Kadam, Nikhil Sakle, Harshad Kapare et al.
2026-10-09 · DOI: 10.1007/s00280-026-04970-1Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders
Yi-Lun Wang, Tsung-Yen Chang, Shih-Hsiang Chen, Yi-Wen Hsiao et al.
2026-10-03 · DOI: 10.1007/s00280-026-04966-xAssociation of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients
Iago Zang Pires, Alexandre Yamada Fujimura, Marília Oberto da Silva Gobbo, Renan Yuji Ura Sudo et al.
2026-09-24 · DOI: 10.1007/s00280-026-04962-1Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy
Tuğba Önder, Öztürk Ateş, Mehmet Emin Yılmaz, Ayşe Ocak Duran et al.
2026-09-24 · DOI: 10.1007/s00280-026-04960-3Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study
Robert Bell, Lisa M O’Brien, Eunice Yuen, Dan Liu et al.
2026-09-24 · DOI: 10.1007/s00280-026-04951-4Correction: Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib
Agata Sałek-Zań, Mirosława Püsküllüoğlu, Agnieszka Stąpór, Justyna Jaworska et al.
2026-09-19 · DOI: 10.1007/s00280-026-04945-2Modulating PI3K/Akt/mTOR-driven autophagy in liver cancer. The role of phytochemicals
Poonam Lal, Jitendra Patel
2026-09-17 · DOI: 10.1007/s00280-026-04949-yOutcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients
Supavich Tannumsaeng, Usanarat Anurathapan, Arpatsorn Sermcheep, Pattara Kanjanakan et al.
2026-09-17 · DOI: 10.1007/s00280-026-04952-3Risk factors associated with febrile neutropenia in patients with esophageal cancer receiving 5-fluorouracil plus cisplatin combination chemoradiotherapy
Daiki Eto, Ken Shiraiwa, Ryota Tanaka, Takahiro Sumimoto et al.
2026-09-17 · DOI: 10.1007/s00280-026-04948-zCharacterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies
Vanessa Gonzalez-Covarrubias, Andrea Morales-Alfaro, Oscar Bonilla-Jimenez, Mauricio Rodríguez-Dorantes et al.
2026-09-17 · DOI: 10.1007/s00280-026-04955-0Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer
Evangelia Sereti, Susan Evans-Axelsson, Jan Törnell, Stefan Rehnmark et al.
2026-09-17 · DOI: 10.1007/s00280-026-04946-1Targeting ALDH2 with Alda-1 to reverse cisplatin resistance in lung adenocarcinoma
Meidong Zhou, Fengjuan Tang, Zhiling Qu, Nan Luo et al.
2026-09-17 · DOI: 10.1007/s00280-026-04954-1CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas
Leire Balaguer-Lluna, Clàudia Resa-Parés, Lucas Brstilo, Alberto Gómez-Caballero et al.
2026-09-17 · DOI: 10.1007/s00280-026-04950-5Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer
Mehmet Fatih Ozbay, Fikret Atlım, Sertac Vurgun, Mehmet Hunur et al.
2026-09-17 · DOI: 10.1007/s00280-026-04953-2Reviews
Community Reviews
Version History
October 9, 2026 at 10:01 pm
October 2, 2026